{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-246740","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2022-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.776051+00:00","generated_at":"2026-06-23T08:47:12.725003+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Agios appoints Cecilia Jones as CFO effective Sept 26; replaces Jonathan Biller","bullets":["Cecilia Jones appointed CFO, effective Sept 26, 2022, replacing Jonathan Biller who resigned Sept 16 to become CLO at Vertex.","Jones previously CFO at LogicBio; 10+ years at Biogen in various finance roles including VP of R&D and BD finance.","Compensation: $475k base salary, 45% target annual bonus, $1.875M stock option, $625k RSUs, $300k PSUs.","Stock option vests: 25% on first anniversary, then monthly through year 4; RSUs vest equally over 3 years.","Company highlights PYRUKYND commercial launch and five pivotal trials; Jones to lead financial strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-246740","json":"https://secwatch.observer/filing/0001193125-22-246740.json","markdown":"https://secwatch.observer/filing/0001193125-22-246740.md","text":"https://secwatch.observer/filing/0001193125-22-246740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522246740/0001193125-22-246740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522246740/d367124d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:47:12.725003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5701e5221","claim":"Cecilia Jones was appointed as Chief Financial Officer at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"On September 15, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) appointed Cecilia Jones as the Company’s Chief Financial Officer effective as of September 26, 2022 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522246740/0001193125-22-246740-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}